This report was first published by Endpoints News. To see the original version, click here
While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review.
The analysis, shared as a preprint, spotlights the fierce competition between Lilly and Novo in the weight loss drug market. Both companies have been trying to edge the other out by showcasing value-added drug features as well as investing in next-generation approaches and advancing oral formulations.
您已阅读17%（586字），剩余83%（2870字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。